• Company
• ‘Global healthcare M&A to recover this year... AI-China’
• by Cha, Jihyun Jan 15, 2025 05:53am

• Company
• Cholangiocarcinoma·AML targeted anticancer drug 'Tibsovo'
• by Eo, Yun-Ho Jan 15, 2025 05:53am

• Company
• Samsung Biologics signs largest CMO deal…KRW 2 Trillion
• by Cha, Jihyun Jan 15, 2025 05:52am

• Company
• Hanmi leads the prescription market for 7 consecutive years
• by Chon, Seung-Hyun Jan 15, 2025 05:52am

• Company
• 'Leclaza·Rybrevant comb therapy' wins nod in KOR
• by Son, Hyung Min Jan 14, 2025 05:56am

• Company
• Samsung Bioepis partners with Teva for Soliris biosimilar
• by Cha, Jihyun Jan 14, 2025 05:56am

• Company
• Will biotech companies continue 'K-Bio' success?
• by Moon, sung-ho Jan 13, 2025 05:53am

• Company
• Samsung Bioepis to indirectly sell Soliris biosimilar in US
• by Cha, Jihyun Jan 13, 2025 05:53am

• Company
• Wegovy can be prescribed in tertiary hospitals in KOR
• by Eo, Yun-Ho Jan 13, 2025 05:53am

• Company
• Imported API from China·India reaches 50%
• by Kim, Jin-Gu Jan 13, 2025 05:53am